2023-08-11
Using an RNA-based drug delivered to multiple myeloma blood cancer cells by targeted lipid nanoparticles, researchers at Tel Aviv University (TAU) destroyed 90% of the cells under laboratory conditions and 60% of the cells in human tissues.
2023-08-10
